*After the Failure of Docetaxel Is There A Best Sequence For Other Treatments?: Results of an Italian Multicenter Study

As we all know there are now a number of new drugs available to treat castrate resistant metastatic prostate cancer (mCRPC). The availability of these new drugs (abiraterone acetate aka Zytiga, cabazitaxel aka Jevtana, and enzalutamide aka Xtandi) for use in men with mCRPC after the failure of chemotherapy (with docetaxel) has opened a number [...]

Understanding the Complexities of Bone Metastases in Prostate Cancer

Our bones operate in a balanced and dynamic system, which in the normal situation keep them strong. Bones are constantly being eliminated and then remade to keep them healthy and read to support our frame. This normal process involves two major kinds of bone cells that work together, in balance, to keep bones healthy and [...]

Radiologic Progression Free Survival Might Predict Treatment Response and Survival

In a recent publication it was suggested that radiographic progression-free survival (rPFS) in men with metastatic castration-resistant prostate cancer (mCRPC) was highly consistent and highly associated with overall survival. This reproducible quantitative find could have implications for the interim measurement of treatment response in future studies, according to Dr. Michael J. Morris of Memorial Sloan [...]

Liver Metastases and ECF – A Possible Treatment In A Not Good Situation

Liver metastases are uncommon in men with castrate resistant prostate cancer (CRPC). Having liver metastases is associated with more serious disease and shorter survival. How to treat men with liver metastases is still not very clear. It is felt that more active treatment might benefit these men. A standard regimen for treating gastric cancer is [...]

On the Horizon – Circulating Tumor Cells in the Clinic – We are Waiting

It isn’t here yet, but it very much is here! What am I talking about? Circulating tumor cells (CTCs) are going to become a clear winner for us as the concept of using them finds its way into commercialization. Metastatic castration resistant prostate cancer (mCRPC) is difficult to evaluate using our less than stellar conventional [...]

Go to Top